With his interests in IP development, biotechnology innovation policy, and R&D, Luiz Otávio Pimentel, president of Brazil’s patent office, tells LSIPR of his aims to improve the country’s IP performance.
The healthcare industry and governments around the world are turning to precision medicine as an opportunity and a potential saviour. Daniel Lim of Kirkland & Ellis discusses the issues around translating the promise of precision medicine into real world clinical practice.
Drug companies can take heart from a range of best practices in the battle against counterfeit medicines, as LSIPR finds out.
As innovation in the CRISPR field continues across the world, questions are being asked about the role of regulating such a powerful tool, while discussions around licensing the technology continue, as LSIPR reports.
As a rival to CRISPR in the gene-editing field, zinc finger nuclease technology is making a name for itself. LSIPR hears from Sandy Macrae, CEO of Sangamo Therapeutics, one of the key players in this area.
Pharma companies with an interest in protecting clinical trial data in Mexico should follow international developments rather than looking closer to home, say Anna Arroyo and Fernando Granados of Uhthoff Gómez Vega & Uhthoff.
Mexico’s guidelines on the advertising of alcoholic beverages should be reviewed by the courts because of concerns about their lawfulness, as Daniel Sanchez and Victor Ramirez of Olivares report.
Brazil’s IP office now expedites patent applications directed to the Zika virus and other neglected diseases, as Ana Paula Jardim and Andréa Granthon of Luiz Leonardos report.
Product development partnerships are likely to provide great opportunities for companies seeking to market biosimilar products in Brazil, where there is a huge reliance on public healthcare. Alice Rayol Sandes of Di Blasi, Parente & Associados has more.
As Mexico prepares for a presidential election in 2018, pharma IP owners are hoping that the progress made in trade negotiations is not undone. Hector Chagoya of Becerril Coca & Becerril reports.